company background image
524731 logo

Jenburkt Pharmaceuticals BSE:524731 Stock Report

Last Price

₹843.15

Market Cap

₹3.7b

7D

-1.2%

1Y

17.2%

Updated

14 Jun, 2024

Data

Company Financials

Jenburkt Pharmaceuticals Limited

BSE:524731 Stock Report

Market Cap: ₹3.7b

Jenburkt Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jenburkt Pharmaceuticals
Historical stock prices
Current Share Price₹843.15
52 Week High₹925.00
52 Week Low₹586.90
Beta0.64
1 Month Change5.97%
3 Month Change20.43%
1 Year Change17.21%
3 Year Change74.20%
5 Year Change61.21%
Change since IPO11,775.35%

Recent News & Updates

Recent updates

Shareholder Returns

524731IN PharmaceuticalsIN Market
7D-1.2%1.7%2.7%
1Y17.2%53.9%44.9%

Return vs Industry: 524731 underperformed the Indian Pharmaceuticals industry which returned 54% over the past year.

Return vs Market: 524731 underperformed the Indian Market which returned 44.7% over the past year.

Price Volatility

Is 524731's price volatile compared to industry and market?
524731 volatility
524731 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.5%
10% most volatile stocks in IN Market9.4%
10% least volatile stocks in IN Market4.3%

Stable Share Price: 524731 has not had significant price volatility in the past 3 months.

Volatility Over Time: 524731's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985724Ashish Bhutawww.jenburkt.com

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical formulations primarily in india. it offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, anti-fungals, anti-ulcerants/antacids, aphrodisiacs, anti-malarials, anthelmintics, and anti- diabetics, as well as consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries worldwide.

Jenburkt Pharmaceuticals Limited Fundamentals Summary

How do Jenburkt Pharmaceuticals's earnings and revenue compare to its market cap?
524731 fundamental statistics
Market cap₹3.72b
Earnings (TTM)₹259.77m
Revenue (TTM)₹1.42b

14.3x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524731 income statement (TTM)
Revenue₹1.42b
Cost of Revenue₹304.11m
Gross Profit₹1.12b
Other Expenses₹855.78m
Earnings₹259.77m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)58.86
Gross Margin78.58%
Net Profit Margin18.30%
Debt/Equity Ratio0%

How did 524731 perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

26%

Payout Ratio

Does 524731 pay a reliable dividends?

See 524731 dividend history and benchmarks
When do you need to buy 524731 by to receive an upcoming dividend?
Jenburkt Pharmaceuticals dividend dates
Ex Dividend DateJul 23 2024
Dividend Pay DateAug 29 2024
Days until Ex dividend37 days
Days until Dividend pay date74 days

Does 524731 pay a reliable dividends?

See 524731 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.